Why the study?
The recommended duration of DAPT after PCI with a drug-eluting stent has shifted from 1 year for all to a personalized approach balancing ischemia and bleeding risks.
DAPT duration after PCI should be personalized based on a patient's specific ischemic and bleeding risks rather than applying a universal 1-year rule.
The recommended duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention with a drug-eluting stent has changed from 1 year for all to a more personalized approach based on the patient's risks of ischemia and bleeding. The trend is toward shorter treatment in view of lower rates of late and very late stent thrombosis with newer drug-eluting stents and the risk of bleeding with DAPT. But some patients at high risk of ischemic events and low risk of bleeding may benefit from longer treatment.
No takes yet. Share an insight, caveat, or question.
Howard et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: